U
UNIQURE NV
NASDAQ: QURE (uniQure N.V.)
Kemas kini terakhir: 1 jam lalu26.65
-1.15 (-4.14%)
| Penutupan Terdahulu | 27.80 |
| Buka | 27.80 |
| Jumlah Dagangan | 2,235,100 |
| Purata Dagangan (3B) | 2,652,447 |
| Modal Pasaran | 1,660,072,832 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.93 |
| Harga / Jualan (P/S) | 81.31 |
| Harga / Buku (P/B) | 6.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -2,815.25% |
| EPS Cair (TTM) | -4.38 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -81.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,522.46% |
| Nisbah Semasa (MRQ) | 11.99 |
| Aliran Tunai Operasi (OCF TTM) | -166.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.89 M |
| Pulangan Atas Aset (ROA TTM) | -15.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -241.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | uniQure N.V. | Menurun | Menaik |
AISkor Stockmoo
1.9
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.88 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.09% |
| % Dimiliki oleh Institusi | 91.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 4,444,444 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 3,988,971 |
| Aberdeen Group Plc | 31 Dec 2025 | 3,678,640 |
| Jennison Associates Llc | 31 Dec 2025 | 1,371,190 |
| Fred Alger Management, Llc | 30 Sep 2025 | 1,290,391 |
| 683 Capital Management, Llc | 30 Sep 2025 | 1,070,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (HC Wainwright & Co., 162.66%) | Beli |
| Median | 45.00 (68.86%) | |
| Rendah | 31.00 (Barclays, 16.32%) | Pegang |
| Purata | 47.78 (79.29%) | |
| Jumlah | 7 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 25.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 31.00 (16.32%) | Pegang | 23.02 |
| Stifel | 11 Dec 2025 | 40.00 (50.09%) | Beli | 19.75 |
| Mizuho | 09 Dec 2025 | 33.00 (23.83%) | Beli | 20.78 |
| Chardan Capital | 04 Dec 2025 | 53.00 (98.87%) | Beli | 22.74 |
| 11 Nov 2025 | 53.00 (98.87%) | Beli | 30.84 | |
| Wells Fargo | 12 Nov 2025 | 60.00 (125.14%) | Beli | 30.12 |
| Leerink Partners | 10 Nov 2025 | 60.00 (125.14%) | Beli | 26.15 |
| Goldman Sachs | 04 Nov 2025 | 38.00 (42.59%) | Pegang | 30.44 |
| HC Wainwright & Co. | 04 Nov 2025 | 70.00 (162.66%) | Beli | 30.44 |
| RBC Capital | 04 Nov 2025 | 45.00 (68.86%) | Beli | 30.44 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Jan 2026 | Pengumuman | uniQure Announces Type A Meeting Scheduled with FDA |
| 04 Dec 2025 | Pengumuman | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
| 10 Nov 2025 | Pengumuman | uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
| 06 Nov 2025 | Pengumuman | uniQure to Announce Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |